Fast Five Quiz: Direct Oral Anticoagulant Therapy for Atrial Fibrillation

Sandeep K. Goyal, MD


April 02, 2020

Andexanet alfa is approved by the US Food and Drug and Administration (FDA) and the European Medicines Agency (EMA) as a reversal agent for apixaban, edoxaban, and rivaroxaban; and idarucizumab is approved by the FDA and EMA as a reversal agent for dabigatran. 

Fresh frozen plasma, 3-FPCC, 4-FPCC, and vitamin K are used to reverse anticoagulation in patients taking VKAs. Anti-inhibitor coagulant complex is administered to control or prevent bleeding in patients with hemophilia A or B.

Learn more about andexanet alfa and idarucizumab.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.